Literature DB >> 18663119

Major neurological events following foam sclerotherapy.

R G Bush1, M Derrick, D Manjoney.   

Abstract

AIM: This report describes two complications of severe neurologic alterations (TIA, CVA) after foamed sclerotherapy injection.
METHODS: Using foam sclerotherapy in accepted concentrations, volume, and in standard ratio of air to sclerosant, two serious neurologic complications occurred.
RESULTS: In both cases described, unknown atrial communications existed resulting in foam emboli. One case involving the vertebral system resolved without treatment. The other involving the cerebral system was treated with hyperbaric oxygen.
CONCLUSIONS: Foam sclerotherapy can cause serious neurologic phenomenon even though the incidence is rarely described. Immediate treatment with 100% O2 and possible hyperbaric O2 therapy should be considered.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18663119     DOI: 10.1258/phleb.2007.007073

Source DB:  PubMed          Journal:  Phlebology        ISSN: 0268-3555            Impact factor:   1.740


  12 in total

1.  Paradoxical cerebral air embolism causing large vessel occlusion treated with endovascular aspiration.

Authors:  Patrick J Belton; Ashish Nanda; Syeda L Alqadri; Gurpreet S Khakh; Premkumar Nattanmai Chandrasekaran; Christopher Newey; William E Humphries
Journal:  BMJ Case Rep       Date:  2016-07-18

Review 2.  Visual loss following sclerotherapy for varicose veins.

Authors:  James Chiung Yoong Leong; Nicholas Robert Johnston
Journal:  BMJ Case Rep       Date:  2011-01-25

3.  Arterial and Venous Air Emboli in Health Care.

Authors:  Gerard J Myers
Journal:  J Extra Corpor Technol       Date:  2021-09

4.  Venous ulcers: new options in treatment: minimally invasive vein surgery.

Authors:  Honesto Poblete; Steven Elias
Journal:  J Am Col Certif Wound Spec       Date:  2009-05-01

5.  Treatment of varicose veins.

Authors:  Raha Nael; Suman Rathbun
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-04

Review 6.  Polidocanol for endovenous microfoam sclerosant therapy.

Authors:  David M Eckmann
Journal:  Expert Opin Investig Drugs       Date:  2009-12       Impact factor: 6.206

7.  Benefits of polidocanol endovenous microfoam (Varithena®) compared with physician-compounded foams.

Authors:  Dario Carugo; Dyan N Ankrett; Xuefeng Zhao; Xunli Zhang; Martyn Hill; Vincent O'Byrne; James Hoad; Mehreen Arif; David D I Wright; Andrew L Lewis
Journal:  Phlebology       Date:  2015-06-01       Impact factor: 1.740

8.  A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of Varithena® (polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence.

Authors:  Kathleen Gibson; Lowell Kabnick
Journal:  Phlebology       Date:  2016-07-09       Impact factor: 1.740

9.  A multicenter, randomized, placebo-controlled trial of endovenous thermal ablation with or without polidocanol endovenous microfoam treatment in patients with great saphenous vein incompetence and visible varicosities.

Authors:  Michael Vasquez; Antonios P Gasparis
Journal:  Phlebology       Date:  2016-03-07       Impact factor: 1.740

Review 10.  Latest Innovations in the Treatment of Venous Disease.

Authors:  Robert R Attaran
Journal:  J Clin Med       Date:  2018-04-11       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.